Set Beliefs Inhibit Science. Judah Folkman Says

Weil, Nancy
April 2004
Bio-IT World;Apr2004, Vol. 3 Issue 4, p18
Academic Journal
Forecasts the development of a treatment for cancer years before the tumors show up. Need for biomarkers that would reveal which patients are going to develop cancer; Development of angiogenesis inhibitors by drug companies; Role of people with Down Syndrome in the study of aniogenesis inhibitors.


Related Articles

  • Limiting supply.  // Nature Reviews Cancer;Aug2008, Vol. 8 Issue 8, p577 

    The use of agents that modulate tumour angiogenesis has led to improvements in patient care, and tumour angiogenesis remains an important area for cancer research. As more anti-angiogenic agents proceed through clinical development, it is important to consider what we now know about the effects...

  • A new role for NF-κB in angiogenesis inhibition. Tabruyn, S. P.; Griffioen, A. W. // Cell Death & Differentiation;Aug2007, Vol. 14 Issue 8, p1393 

    The author reflects on the new role for NF-kB in angiogenesis inhibition. He highlights the fact that angiogenesis is considered a promising target in the treatment of cancer. He then indicates that NF-kB is involved in the regulation of migration and/or proliferation or survival of endothelial...

  • The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway. Hamzehzadeh, Leila; Atkin, Stephen L.; Majeed, Muhammed; Butler, Alexandra E.; Sahebkar, Amirhossein // Journal of Cellular Physiology;Oct2018, Vol. 233 Issue 10, p6530 

    Despite significant advances in treatment modalities, millions of cancer‐related deaths continue to occur annually, often as a consequence of developing resistance against the range of available chemotherapeutic drugs. Furthermore, available anti‐cancer chemotherapeutic agents show...

  • Pazopanib reduced tumors in lung cancer. Blazek, Nicole // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p34 

    The article focuses on the result of the phase-2 proof-of-concept clinical trial using pazopanib, an oral angiogenesis inhibitor, to treat patients who had early-stage non-small cell lung cancer. Researcher Nassar Altorki and colleagues concluded that the therapeutic regimen reduced the overall...

  • Managing Cancer in the Workplace.  // Fairfield County Business Journal;3/9/2015, Vol. 51 Issue 10, p9 

    The article offers information on Managing Cancer in the Workplace seminar to be held at the JMW Consultants Landmark Square in Stamford, Connecticut on March 26, 2015.

  • IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway. Yu, Xi-Xiang; Hu, Zhe; Shen, Xian; Dong, Li-Yang; Zhou, Wei-Zhong; Hu, Wen-Hao // Digestive Diseases & Sciences;May2015, Vol. 60 Issue 5, p1265 

    Background: As a pro-inflammatory cytokine, IL-33 has been demonstrated to play an important role in tumor progression. It is reported that IL-33 is highly expressed in the serum and tumor tissues of patients with gastric cancer. However, the function of IL-33 in gastric cancer remains elusive....

  • Endostatin: Are We Waiting For Godot? Whitworth, Ariel // JNCI: Journal of the National Cancer Institute;6/7/2006, Vol. 98 Issue 11, p731 

    The article focuses on the clinical trials designed to study the effects of angiogenesis inhibitor endostatin in cancer patients in the U.S. Initial laboratory tests were positive; endostatin blocked tumor growth and decreased the incidence of lesions in rats with breast carcinomas. Other...

  • Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology. Verhoef, C.; de Wilt, J. H.W.; Verheul, H. M.W. // Current Pharmaceutical Design;Jul2006, Vol. 12 Issue 21, p2623 

    In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. Surgeons, radiotherapists as well as medical oncologists have been investigating with much effort and enthusiasm the translation of these agents from the preclinical setting into treatment...

  • Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango. Thijssen, Victor L. J. L.; van Beijnum, Judy R.; Mayo, Kevin H.; Griffioen, Arjan W. // Current Pharmaceutical Design;Dec2007, Vol. 13 Issue 35, p3576 

    The development of novel treatment strategies for therapy of angiogenesis-dependent diseases requires identification of specific tumor endothelial cell markers to which therapeutic agents can be targeted. This can be achieved by random or targeted approaches. Random approaches are based on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics